Uric acid metabolism regulation

Uric acid metabolism regulation encompasses the coordinated control of uric acid synthesis, transport, excretion, and degradation. In humans, uric acid originates largely from the degradation of purines, via the action of enzymes such as xanthine oxidase (which converts hypoxanthine and xanthine into uric acid). Since humans lack uricase to further break down uric acid, its serum levels are tightly regulated through excretory pathways in the kidney and gut, involving specialized transporters such as SLC22A12 (URAT1), SLC2A9 (GLUT9), and ABCG2 (BCRP). Dysregulation of these pathways can lead to hyperuricemia and related diseases, most notably gout, and can also contribute to cardiovascular, renal, and metabolic diseases. Drugs targeting uric acid metabolism include xanthine oxidase inhibitors (e.g., allopurinol, febuxostat) and uricosuric agents (e.g., probenecid, lesinurad); these intervene by either reducing uric acid synthesis or increasing its elimination. Uric acid itself is a dual-function molecule in physiology, acting as both a pro-inflammatory mediator and a potent antioxidant; hence its regulation is complex and therapeutically challenging. If structured data is needed, it is strongly recommended to select a specific molecular target within this process (e.g., "Xanthine oxidase", "Urate transporter SLC22A12 (URAT1)") for further detailed characterization.

Inhibition of xanthine oxidase to reduce uric acid production; Inhibition of urate transporters to increase uric acid excretion; Activation or inhibition of renal/gut uric acid transport pathways.